BC Week In Review | Sep 12, 2016
Clinical News

AK001: Phase II started

Allakos began a double-blind, placebo-controlled, international Phase II trial to evaluate 2 dose levels of AK001 in about 70 patients. Allakos Inc. , San Carlos, Calif.   Product: AK001   Business: Inflammation   Molecular target: Undisclosed...
BC Week In Review | Feb 1, 2016
Clinical News

AK001: Phase I ongoing

Allakos completed dosing of 34 healthy volunteers and patients in a double-blind, placebo-controlled, U.S. Phase I trial evaluating single ascending doses of parenteral AK001. Allakos Inc. , San Carlos, Calif.   Product: AK001   Business: Inflammation...
Items per page:
1 - 2 of 2